Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD.
Giulio G StefaniniCarlo BriguoriDavide CaoUsman BaberSamantha SartoriZhongjie ZhangGeorge DangasDominick J AngiolilloShamir MehtaDavid Joel CohenStuart J PocockDariusz DudekJavier EscanedCharles Michael GibsonRobert J GilKurt HuberUpendra KaulRan KornowskiMitchell W KrucoffVijay KunadianDavid J MoliternoE Magnus OhmanKeith G OldroydGennaro SardellaSamin K SharmaRichard A ShlofmitzGiora WeiszBernhard WitzenbichlerStuart J PocockRoxana MehranPublished in: European heart journal (2021)
Among CKD patients undergoing PCI, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events as compared with ticagrelor plus aspirin.
Keyphrases
- percutaneous coronary intervention
- antiplatelet therapy
- acute coronary syndrome
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- patients undergoing
- chronic kidney disease
- atrial fibrillation
- coronary artery bypass grafting
- combination therapy
- open label
- coronary artery bypass
- low dose
- cardiovascular events
- heart failure
- type diabetes
- cardiovascular disease
- randomized controlled trial
- study protocol
- left ventricular